NeoGenomics (NEO) to Release Quarterly Earnings on Tuesday

Posted by Brian Himes on Jul 21st, 2026

NeoGenomics (NASDAQ:NEO – Get Free Report) is anticipated to announce its Q2 2026 results after the market closes on Tuesday, July 28th. Analysts expect NeoGenomics to post earnings of $0.03 per share and revenue of $196.9250 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 4:30 PM ET.

NeoGenomics (NASDAQ:NEO – Get Free Report) last announced its earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The company had revenue of $186.67 million during the quarter, compared to analyst estimates of $184.54 million. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, analysts expect NeoGenomics to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Stock Down 2.5%

NEO opened at $14.24 on Tuesday. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $15.57. The company has a market capitalization of $1.85 billion, a PE ratio of -18.49 and a beta of 1.74. The firm’s 50 day simple moving average is $11.73 and its two-hundred day simple moving average is $10.58.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Weiss Ratings raised NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. Benchmark raised NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Wednesday, April 29th. Finally, TD Cowen reissued a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, NeoGenomics has a consensus rating of “Hold” and a consensus target price of $13.86.

Read Our Latest Stock Analysis on NeoGenomics

Insider Activity at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the transaction, the director owned 91,422 shares of the company’s stock, valued at $1,032,154.38. This represents a 5.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its stake in NeoGenomics by 69.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,218,727 shares of the medical research company’s stock worth $26,093,000 after acquiring an additional 912,788 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of NeoGenomics during the 4th quarter valued at approximately $363,000. AQR Capital Management LLC boosted its position in shares of NeoGenomics by 121.7% during the 4th quarter. AQR Capital Management LLC now owns 146,352 shares of the medical research company’s stock valued at $1,721,000 after acquiring an additional 80,348 shares during the last quarter. First Light Asset Management LLC grew its holdings in shares of NeoGenomics by 1.1% in the fourth quarter. First Light Asset Management LLC now owns 10,035,063 shares of the medical research company’s stock valued at $118,012,000 after purchasing an additional 107,794 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in shares of NeoGenomics in the fourth quarter valued at $10,414,000. 98.50% of the stock is owned by institutional investors.

About NeoGenomics

(Get Free Report)

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.